PrognomiQ Inc

PrognomiQ Inc is a biopharma and biotechnology startup based in the United States, founded in 2020. The company's mission is to "Transform healthcare and early disease detection through the power of multi-omics data." PrognomiQ aims to generate proteomic information with high accuracy, scale, and speed, complemented by genomic, metabolomic, and other health information. This approach enables the development of first-in-class test products for early disease detection and treatment. The company utilizes a proprietary multi-omics platform incorporating Proteograph technology platform from Seer (NASDAQ: SEER), the life science tools company it spun out of in 2020. PrognomiQ addresses the previously untapped potential of proteomics data by leveraging next-generation tools to elucidate complex proteomics at scale. By merging the newly accessible proteomics data with genomics and other data like metabolomics, PrognomiQ aims to generate powerful multi-omics data, unlocking the potential for early disease detection and treatment when diseases are most likely to be cured. The startup recently secured a $46.00M Venture Round investment on 15 March 2022 from a notable group of investors, including Wing VC, Emerson Collective, Invus, T. Rowe Price, aMoon, Catalio Capital Management, Fidelity, Maverick Global Ventures, and Bruker. PrognomiQ's innovative approach and strategic partnerships position it as a promising player in the evolving landscape of healthcare and biotechnology.